Mesoblast (ASX:MSB) Secures Medicaid Agreement for Ryoncil®
Medicaid National Drug Rebate Agreement
Mesoblast has entered into the Medicaid National Drug Rebate Agreement with the U.S. Centers for Medicare & Medicaid Services for Ryoncil® (remestemcel-L). This agreement ensures inpatient and outpatient access to Ryoncil® for approximately 40% of U.S. children covered by Medicaid suffering from steroid-refractory acute graft versus host disease (SR-aGvHD). Mandatory coverage will commence on July 1, 2025.
Commencement of Treatment
The first three children with SR-aGvHD will begin treatment with Ryoncil® this week. Ryoncil® is an allogeneic MSC therapy approved by the FDA for pediatric patients aged 2 months and older, including adolescents and teenagers, with SR-aGvHD. The recommended treatment course involves two intravenous infusions per week for four consecutive weeks.
Executive Comments
Mesoblast Chief Executive Dr. Silviu Itescu stated, “We are delighted to be commencing treatment with Ryoncil® for children suffering with SR-aGvHD and are proud that the product is available to all children in the U.S. irrespective whether they have private insurance or Medicaid. This is a significant commercial achievement by our team and partners who are driven by an overwhelming desire to help children and their families faced with this devastating disease.”
Motley Fool contributor ..... has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
